Following Donald Trump’s shocking victory, and California Proposition 61’s defeat, drug-pricing policy fears stoked by Hillary Clinton’s campaign practically evaporated overnight. This helped send biotech stocks Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Exelixis (NASDAQ: EXEL) soaring by double digits following the election. Conversely, healthcare providers benefiting from the Affordable Care Act, or Obamacare, were pummeled.